Immuneering Corporation (IMRX)
| Market Cap | 285.32M +304.5% |
| Revenue (ttm) | n/a |
| Net Income | -54.44M |
| EPS | -1.06 |
| Shares Out | 64.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,010,446 |
| Open | 4.470 |
| Previous Close | 4.410 |
| Day's Range | 4.255 - 4.520 |
| 52-Week Range | 2.060 - 10.080 |
| Beta | 0.38 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+285.49%) |
| Earnings Date | May 15, 2026 |
About IMRX
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinica... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for IMRX stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 285.49% from the latest price.
News
Immuneering appoints Andrew Gengos as CFO
Immuneering (IMRX) announced the appointment of Andrew Gengos as CFO, effective July 16. Gengos most recently served as CFO and head of corporate development at Terns Pharmaceuticals. At Immuneering, ...
Immuneering Appoints Andrew Gengos as Chief Financial Officer
- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Imm...
Immuneering Transcript: AGM 2026
The meeting covered director elections and auditor ratification, with both proposals approved. No questions were raised by stockholders, and final vote results will be published in a Form 8-K filing.
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary endp...
Immuneering announces updated clinical data from atebimetinib combination trial
Immuneering (IMRX) announced updated clinical data from its ongoing Phase 2a trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic d...
Immuneering Transcript: Study result
Phase II-A data for atebimetinib plus modified gemcitabine nab-paclitaxel in first-line pancreatic cancer show a median overall survival of 17.3 months with favorable tolerability and high rates of weight stability. The phase III MAPKeeper 301 trial is now recruiting, and the company is financially positioned to fund operations into 2029.
Immuneering Press release: Study result
Immuneering issued a press release on June 1, 2026, disclosing material business information to investors.
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Can
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering reports Q1 EPS (21c), consensus (25c)
“We are excited that new survival data from 55 first-line pancreatic cancer patients treated with atebimetinib + mGnP in our Phase 2a clinical trial will be reported in an oral…
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
- New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual Meeting - - Pivotal P...
Immuneering Earnings release: Q1 2026
Immuneering released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Immuneering Quarterly report: Q1 2026
Immuneering has published its Q1 2026 quarterly earnings report on May 15, 2026.
Immuneering announces updated data from Phase 2a trial for atebimetinib
Immuneering (IMRX) Corporation announced that updated data from the Phase 2a clinical trial evaluating atebimetinib, IMM-1-104, in combination with modified gemcitabine/nab-paclitaxel in first-line pa...
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health -
Immuneering announces presentation of new genetic data at 2026 AACR
Immuneering (IMRX) announced the presentation of new genetic data at the 2026 American Association for Cancer Research, AACR, Annual Meeting taking place April 17-22, 2026 in San Diego, CA. Key…
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors rarel...
Immuneering Proxy statement: Proxy filing
Immuneering filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Immuneering Proxy statement: Proxy filing
Immuneering filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Immuneering Transcript: 25th Annual Needham Virtual Healthcare Conference
Atebimetinib demonstrated a 64% 12-month overall survival in first-line pancreatic cancer, with robust tolerability and unique mechanisms supporting both efficacy and quality of life. The pivotal phase III trial is set to begin dosing mid-year, with a top-line OS readout expected in about two years.
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today anno...
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability
Immuneering Transcript: Leerink Global Healthcare Conference 2026
Deep Cyclic Inhibitors, led by atebimetinib, show promising survival and tolerability in First-Line pancreatic cancer, with 64% 12-month survival and minimal added toxicity. A pivotal phase III trial is launching, and combination studies in lung cancer are planned.
Immuneering price target lowered to $12 from $13 at Piper Sandler
Piper Sandler lowered the firm’s price target on Immuneering (IMRX) to $12 from $13 and keeps an Overweight rating on the shares following the company’s Q4 update. Timing for near-term…
Immuneering Annual report: Q4 2025
Immuneering has published its Q4 2025 annual report on March 6, 2026.